Lactobacillus acidophilus BCMC 12130 (L. acidophilus BCMC 12130)

Lactobacillus acidophilus BCMC 12130 is a specific probiotic bacterial strain utilized as a therapeutic biological agent rather than a traditional molecular drug target. It is a primary constituent of multi-strain probiotic formulations, such as Hexbio, which are clinically indicated for the management of various gastrointestinal conditions, including irritable bowel syndrome (IBS) and chronic constipation. The strain functions by colonizing the human gut, where it produces lactic acid and other metabolites that inhibit the growth of pathogenic bacteria and help restore homeostatic microbial balance. Research indicates that L. acidophilus BCMC 12130 plays a significant role in enhancing the intestinal mucosal barrier and modulating the systemic immune system by influencing the balance of pro- and anti-inflammatory cytokines. While it is generally recognized as safe (GRAS), it is considered 'incorrect' as a target in the pharmacological sense because it acts as the active therapeutic entity. Clinical studies have demonstrated its efficacy in improving bowel transit time and reducing the symptoms of metabolic syndrome when administered as part of a synbiotic regimen.

Other names

L. acidophilus BCMC 12130Lactobacillus acidophilus strain BCMC 12130

As a probiotic, it exerts therapeutic effects by adhering to the intestinal mucosa to prevent pathogen colonization, producing antimicrobial compounds like bacteriocins and organic acids, and modulating the host's immune response via cytokine regulation (e.g., increasing IL-10). It also strengthens tight junctions in the intestinal epithelium to reduce gut permeability.